Clinical Trial Update: Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating plerixafor in combination with donor lymphocyte infusion for relapsed acute leukemia after allogeneic hematopoietic ste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• Donor Lymphocyte Infusion
• Plerixafor (Plerixafor)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Status: UNKNOWN